U.S., Nov. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07228663) titled 'Hip Fracture Surgery Arterial and Venous Thrombotic Events Prevention' on Aug. 16.
Brief Summary: A third of patients undergoing surgery for a hip fracture develop a myocardial injury (i.e., an elevated troponin measurement), and these patients are at substantial risk of death and morbidity. Current prophylaxis strategies focus on preventing venous thromboembolism (VTE); however, arterial events are more common and carry a poor prognosis. The association of acetylsalicylic acid (ASA) 75-100 mg once daily and rivaroxaban 2.5 mg twice a day (the regimen used in the COMPASS trial) might prevent both VTE and arterial cardiovascular even...